LSE - Delayed Quote • GBp
Oxford Biomedica plc (OXB.L)
At close: April 25 at 5:05 PM GMT+1
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
119,023.00
139,989.00
142,797.00
87,728.00
Cost of Revenue
64,031.00
70,808.00
60,157.00
41,655.00
Gross Profit
54,992.00
69,181.00
82,640.00
46,073.00
Operating Expense
138,659.00
120,739.00
61,707.00
50,936.00
Operating Income
-83,667.00
-51,558.00
20,933.00
-4,863.00
Net Non Operating Interest Income Expense
-1,150.00
-7,781.00
-888.00
-878.00
Pretax Income
-70,936.00
-45,976.00
19,880.00
-6,572.00
Tax Provision
-750.00
-817.00
869.00
-327.00
Net Income Common Stockholders
-61,630.00
-39,157.00
19,011.00
-6,245.00
Diluted NI Available to Com Stockholders
-61,630.00
-39,157.00
19,011.00
-6,245.00
Basic EPS
-0.64
-0.41
0.23
-0.08
Diluted EPS
-0.64
-0.41
0.22
-0.08
Basic Average Shares
96,404.85
94,829.89
83,484.17
79,944.91
Diluted Average Shares
96,404.85
94,829.89
85,618.67
79,944.91
Total Operating Income as Reported
-61,811.00
-30,220.00
20,768.00
-5,694.00
Rent Expense Supplemental
--
231.00
236.00
173.00
Total Expenses
202,690.00
191,547.00
121,864.00
92,591.00
Net Income from Continuing & Discontinued Operation
-61,630.00
-39,157.00
19,011.00
-6,245.00
Normalized Income
-61,625.05
-39,106.91
19,168.79
-5,455.35
Interest Income
3,140.00
973.00
--
34.00
Interest Expense
4,290.00
8,754.00
888.00
912.00
Net Interest Income
-1,150.00
-7,781.00
-888.00
-878.00
EBIT
-66,646.00
-37,222.00
20,768.00
-5,660.00
EBITDA
-36,588.00
-10,863.00
33,224.00
4,179.00
Reconciled Cost of Revenue
64,031.00
70,808.00
60,157.00
41,655.00
Reconciled Depreciation
30,058.00
26,359.00
12,456.00
9,839.00
Net Income from Continuing Operation Net Minority Interest
-61,630.00
-39,157.00
19,011.00
-6,245.00
Total Unusual Items Excluding Goodwill
-5.00
-51.00
-165.00
-831.00
Total Unusual Items
-5.00
-51.00
-165.00
-831.00
Normalized EBITDA
-36,583.00
-10,812.00
33,389.00
5,010.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-0.05
-0.91
-7.21
-41.35
12/31/2020 - 12/13/1996
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ONT.L Oxford Nanopore Technologies plc
93.10
-9.26%
RENE.L ReNeuron Group plc
3.3750
-2.17%
SCLP.L Scancell Holdings plc
9.60
0.00%
BVXP.L Bioventix PLC
4,425.00
-1.12%
HVO.L hVIVO plc
28.60
+0.35%
OBD.L Oxford BioDynamics Plc
8.20
-8.89%
POLB.L Poolbeg Pharma PLC
11.60
+0.87%
RYH0.F Sareum Holdings plc
0.3040
0.00%
ROQ.L Roquefort Therapeutics plc
4.5500
-4.21%
BRCTF BioArctic AB (publ)
17.75
0.00%